ICOTF - iCo Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0433
0.0000 (0.00%)
At close: 10:42AM EST
Stock chart is not supported by your current browser
Previous Close0.0433
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0433 - 0.0433
52 Week Range0.0200 - 0.2040
Volume0
Avg. Volume6,092
Market Cap3.494M
Beta (3Y Monthly)2.92
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile13 days ago

    iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "This quarter was a period of significant achievement for iCo Therapeutics and its wholly-owned subsidiary, ...

  • Newsfile27 days ago

    iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study

    Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.-iCo Therapeutics announces that it now has sufficient drug supply for a proposed mid-staged clinical trial, which may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B) ...

  • Newsfile2 months ago

    iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.Stated Dr. Peter Hnik, Chief Medical Officer, "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. We ...

  • Newsfile2 months ago

    iCo Therapeutics Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.iCo Therapeutics Australia Pty Ltd. has received full payment of approximately $462,000 Australian dollars (AUD) for R&D expenditures conducted during its past fiscal year, during which the Company conducted a Phase 1 clinical study. Refundable cash tax credits at a reimbursement rate for ...

  • Newsfile3 months ago

    iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of ...

  • Associated Press3 months ago

    Ico Therapeutics: 2Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of 1 cent per share. In the final minutes of trading on Wednesday, the company's shares hit 8 cents. A year ago, they were trading at 4 ...

  • Newsfile3 months ago

    iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "the quarter represented a period of significant achievement for iCo Therapeutics with respect to its two clinical ...

  • Newsfile5 months ago

    iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical study. Previously the Company reported that the study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects, including ...

  • Newsfile6 months ago

    iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

    Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse ...

  • Newsfile6 months ago

    iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment

    Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clinical TrialThe Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B). Subjects ...

  • Associated Press6 months ago

    Ico Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of less than 1 cent. In the final minutes of trading on Wednesday, the company's shares hit 2 cents. A year ago, they ...

  • Newsfile6 months ago

    iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."Recently, we dosed our first subject with our novel Oral Amphotericin B (Oral AmpB) formulation. Strong recruitment has resulted in our dosing of all subjects in three of ...

  • Why iCo Therapeutics Inc’s (CVE:ICO) CEO Pay Matters To You
    Simply Wall St.8 months ago

    Why iCo Therapeutics Inc’s (CVE:ICO) CEO Pay Matters To You

    Leading iCo Therapeutics Inc (TSXV:ICO) as the CEO, Andrew Rae took the company to a valuation of CA$2.53M. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Newsfile8 months ago

    iCo Therapeutics Announces Year End 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").2017 Financial & Operational HighlightsDuring the year, we advanced our oral formulation of Amphotericin B completing our 14-day GLP toxicology study which revealed that oral administration of Amphotericin ...

  • Newsfile8 months ago

    iCo Therapeutics Announces Major Milestone - Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study

    Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B. "Dosing our first patient is a major milestone for iCo Therapeutics and the oral Amphotericin B program" stated Andrew Rae, President and CEO of iCo Therapeutics ...

  • One Thing To Consider Before Buying iCo Therapeutics Inc (CVE:ICO)
    Simply Wall St.8 months ago

    One Thing To Consider Before Buying iCo Therapeutics Inc (CVE:ICO)

    If you are a shareholder in iCo Therapeutics Inc’s (TSXV:ICO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Who Really Owns iCo Therapeutics Inc (CVE:ICO)?
    Simply Wall St.9 months ago

    Who Really Owns iCo Therapeutics Inc (CVE:ICO)?

    I am going to take a deep dive into iCo Therapeutics Inc’s (TSXV:ICO) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...